Entries |
Document | Title | Date |
20080214615 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same - This invention relates to N-methylaminomethyl-isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed. | 09-04-2008 |
20080227815 | Crystal of Indole Derivative Having Piperidine Ring and Process for Production Thereof - A crystal of 1-[1-[2-(7-methoxy-2,2-dimethyl-4-oxochroman-8-yl)-ethyl]piperidin-4-yl]-N-methyl-1H-indole-6-carboxamide fumarate which has peaks at chemical shifts of about 124.0 ppm and about 26.8 ppm in a | 09-18-2008 |
20080227816 | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases - Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and related syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 09-18-2008 |
20080269291 | Chemical Compounds - The invention is directed to novel indolecarboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): | 10-30-2008 |
20080287496 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels - 1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines substituted in the 4- and/or 7-position of the isoindoline ring and optionally further substituted in the 3-position of the 2,6-dioxopiperidine ring reduce the levels of inflammatory cytokines such as TNFα in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline | 11-20-2008 |
20080287497 | TRANSDERMAL METHODS AND SYSTEMS FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS - Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described. | 11-20-2008 |
20080306113 | Methods for treating macular degeneration using 4-(amino)-2-(2,6-dioxo(3-piperidyle))-isoindoline-1,3-dione - Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, alone or in combination with a second active agent and/or surgery. | 12-11-2008 |
20090062343 | Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindol-2-yl)-piperidine-2,6-dione - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 03-05-2009 |
20090069379 | DEUTERIUM-ENRICHED LENALIDOMIDE - The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090131478 | Growth Hormone Secretagogues - A family of peptides and peptidomimetic compounds useful as GHS analogs according to either formula (I) or (II) as depicted below: or a pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification. | 05-21-2009 |
20090137631 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REGULATION OF G- AND/OR GC-RICH NUCLEIC ACID EXPRESSION - Methods and pharmaceutical compositions for regulations of Guanosine- (G-) and/or Guanosine-cytosine-rich (GC-rich) nucleic acid expressions are provided. The methods include a step of interacting the G- and/or GC-rich region of the nucleic acid with thalidomide, and the pharmaceutical compositions include the thalidomide and a pharmaceutical carrier. | 05-28-2009 |
20090149499 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE) - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 06-11-2009 |
20090149500 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 06-11-2009 |
20090149501 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS - The present invention provides novel compounds of Formula (I) | 06-11-2009 |
20090156641 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY - The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are known to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed. | 06-18-2009 |
20090163548 | Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases - Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 06-25-2009 |
20090176832 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 07-09-2009 |
20090192195 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 07-30-2009 |
20090197915 | SIGMA RECEPTOR COMPOUNDS - The present invention relates to compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals. | 08-06-2009 |
20090270453 | ANTI-MANIC EFFECTIVE DOSES OF SERTINDOLE - The present invention relates to uses of an anti-manic effective dose sertindole in the preparation of a pharmaceutical composition for the treatment of mania, and to methods of treating mania comprising administering said effective dose of sertindole. In separate aspects of the invention, said uses and methods are directed to treating manic episodes. | 10-29-2009 |
20090298882 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - Provided are thioxo isoindoline compounds, and pharmaceutically acceptable salts, solvates, and stereoisomers, thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed. | 12-03-2009 |
20100004286 | NOVEL ISOINDOLINONE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST T-TYPE CALCIUM CHANNEL AND METHOD FOR PREPARATION THEREOF - Disclosed are isoindolinone derivatives, represented by Chemical Formula 1, having inhibitory activity against T-type calcium channels, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient. | 01-07-2010 |
20100016363 | Fixed Combination Dosage Forms for the Treatment of Migraine - Therapeutic regimens and dosage forms are disclosed for the treatment of migraine headache. The regimens preferably combine a serotonin receptor agonist, such as sumatriptan, eletriptan or almotriptan, with a fast acting formulation of diclofenac potassium. | 01-21-2010 |
20100016364 | METHOD OF PREDICTIVE DETERMINATION OF RESPONSIVENESS TO PHARMACOLOGICAL INTERVENTION - A diagnostic test for determining the efficacy of 5HT | 01-21-2010 |
20100041703 | RAPID DISINTEGRATION MONOLAYER FILM FOR THE ORAL ADMINISTRATION OF ACTIVE SUBSTANCES - Rapid-disintegration monolayer film for the oral administration of active substances, comprising a water-soluble support containing at least one active substance, characterized in that it comprises a polymeric mixture of a hydrophilic film-forming agent formed from a copolymer of polyvinyl alcohol and of polyethylene glycol (PVA-PEG), of an active substance and of a hydrophilic gelling agent. | 02-18-2010 |
20100063094 | METHODS FOR TREATMENT OF COLORECTAL CANCER USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 03-11-2010 |
20100087484 | AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS - The present invention relates to novel aminoalkoxy arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT | 04-08-2010 |
20100087485 | 4-AMINOPIPERIDINE DERIVATIVES - The present invention relates to compounds of the formula (I) | 04-08-2010 |
20100093798 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes modulators of MIP-1α or CCR-1 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n, ring A, T, V, X, R | 04-15-2010 |
20100093799 | Pharmaceutical Compositions of 3-(4-Amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione - Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal. | 04-15-2010 |
20100099711 | Methods and Compositions Using Immunomodulatory Compounds for The Treatment and Management of Cancers and Other Diseases - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 04-22-2010 |
20100144790 | Use of Thalidomide for Alzheimers Disease Treatment and Prevention - β-secretase (BACE) is a biomarker for MCI and Alzheimer's disease. BACE1 protein level and the enzymatic activity level increase in the brain, and in the CSF in AD and MCI patients. Increased BACE1 levels in CSF are related to neuronal death and synaptic damages, which contribute to AD-related cognitive deficits. BACE1 inhibitors may be used as therapeutic compounds for clinical use for the disease treatment and prevention. Use of Thalidomide, an effective BACE1 inhibitor, reduces the BACE1 enzymetic activity and protein levels, and the Aβ production that marks the neurodegenerative progression associated with AD. | 06-10-2010 |
20100160378 | COMPOSITIONS FOR DRUG ADMINISTRATION - The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. | 06-24-2010 |
20100168168 | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands - The present invention provides aminoaryl sulphonamide derivatives of formula (I), useful in the treatment of a CNS disorder related to or affected by the 5-HT | 07-01-2010 |
20100204276 | INDOLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 08-12-2010 |
20100222388 | Enhanced Migraine Treatments Based on Ghrelin Mimetics - The present invention relates to method of enhancing the absorption of migraine medications and thereby treating migraines by co-administering to a subject in need thereof an effective amount of a ghrelin mimetic or pharmaceutically acceptable salt, hydrate or solvate thereof and at least one migraine medication selected from a serotonin 5-HT | 09-02-2010 |
20100280072 | 2-'4-(HYDROXYMETHYL-PHENYLAMINO) -PIPERIDINE-1-YL!-N- (9H-CARBAZOL-3YL) - ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY - The present invention relates to 1,4-disubstituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals. The substituents are as defined in the present claim | 11-04-2010 |
20100292272 | SUPRAMOLECULAR CO-COLLOIDS PRODUCED USING MACROCYCLIC POLYANIONIC SYSTEMS - The present invention relates to a method preparing co-colloidal dispersions of active hydrophobic substances, such as pharmaceutical products, products having cosmetic properties or any other chemical product. The co-colloidal dispersions thus obtained are characterized in that they are formed by amphiphilic complexes resulting from combinations by non-covalent bonds between a hydrophobic active substance and a suitable hydrophilic molecule. | 11-18-2010 |
20110015228 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 01-20-2011 |
20110021567 | PREPARATION OF LENALIDOMIDE - Processes for the preparation of substantially pure lenalidomide. The application also relates to an enriched, substantially pure, and pure amorphous form of lenalidomide and solid dispersions containing amorphous lenalidomide. | 01-27-2011 |
20110065750 | Solid Forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and Methods of Making the Same - The present invention provides for new crystalline and amorphous forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, and methods of making the same. | 03-17-2011 |
20110077272 | PULMONARY FORMULATIONS OF TRIPTANS - A pharmaceutical composition includes triptans, such as sumatriptan, and may be used in therapy. The composition may be administered via the inhaled route. | 03-31-2011 |
20110152321 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 - The present invention is directed to novel bicyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1. | 06-23-2011 |
20110172273 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES USING LENALIDOMIDE - Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine. | 07-14-2011 |
20110201647 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-[7-FLUORO-1-(2-METHOXY-- ETHYL)-4-TRIFLUOROMETHOXY-1H-INDOL-3-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE - The present invention is directed to an indole benzylamine compound of formula I: | 08-18-2011 |
20110257228 | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING A TRIPTAN COMPOUND AND XYLITOL - The present disclosure relates to aqueous liquid pharmaceutical compositions comprising a) at least one triptan compound, pharmaceutically acceptable salts or hydrates thereof, and b) xylitol. | 10-20-2011 |
20110263649 | CRYSTALLINE FORM OF LENALIDOMIDE AND A PROCESS FOR ITS PREPARATION - The present invention relates to a novel crystalline form of lenalidomide having formula (I) and chemically known as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione. The present invention further relates to a process for the preparation of said novel form and its use in pharmaceutical preparations for the treatment of autoimmune disease, inflammation, inflammatory disease and diseases such as cancer, in particular the management of multiple myeloma. | 10-27-2011 |
20110275671 | DIHYDROINDOLINONE DERIVATIVES - Disclosed are dihydroindolone compounds which can modulate the activity of protein tyrosine kinases, a method for preparing the same, and pharmaceutical compositions comprising the same. Also disclosed are use of such compounds and pharmaceutical compositions thereof in the treatment and/or prophylaxis of protein tyrosine kinase associated diseases in an organism, particularly in the treatment and/or prophylaxis of tumors and fibroblast proliferation associated diseases. | 11-10-2011 |
20110275672 | METHODS FOR TREATING CANCERS USING POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 11-10-2011 |
20110288126 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES - This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an immunomodulatory agent. | 11-24-2011 |
20110288127 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 11-24-2011 |
20110301198 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide. | 12-08-2011 |
20110301199 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof in patients who have been treated with a DNA methyltransferase inhibitor by a combination of ezatiostat or a salt thereof and lenalidomide. | 12-08-2011 |
20120010244 | INDOLE DERIVATIVES AS IKK2 INHIBITORS - The invention is directed to a certain novel compound which is an inhibitor of kinase activity, in particular IKK2 activity. | 01-12-2012 |
20120022106 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 01-26-2012 |
20120029019 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 02-02-2012 |
20120029020 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 02-02-2012 |
20120046315 | INTERMEDIATE AND ORAL ADMINISTRATIVE FORMATS CONTAINING LENALIDOMIDE - The invention relates to non-crystalline lenalidomide in the form of a storage-stable intermediate, i.e. preferably amorphous lenalidomide together with a surface stabiliser in the form of a stable intermediate or a storage-stable intermediate, containing lenalidomide and matrix material, wherein the lenalidomide is present in the form of a solid solution (i.e. molecularly disperse). The invention further relates to methods of producing stable amorphous or molecularly disperse lenalidomide and pharmaceutical formulations containing stable amorphous or molecularly disperse lenalidomide. In a second aspect, the invention advantageously relates to dry-processing methods for lenalidomide, especially amorphous and disperse lenalidomide. | 02-23-2012 |
20120046316 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed. | 02-23-2012 |
20120071509 | PROCESS - The present invention relates to improved processes for preparing 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (I) (lenalidomide) and its intermediate 3-(1-oxo-4-nitro-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione. The present invention further relates to improved processes for preparing lenalidomide crystalline form A, use of said crystalline form A as an active pharmaceutical ingredient or as an intermediate in the preparation of further crystalline or amorphous forms of lenalidomide, compositions comprising lenalidomide crystalline form A and their use in the treatment of disease. | 03-22-2012 |
20120071510 | Method and Composition for Treating Migraines - A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is designed for inhalation for delivery of drugs to the pulmonary circulation in a rapid and therapeutically effective manner. | 03-22-2012 |
20120095049 | NOCICEPTIN ANALOGS - A compound of the formula (I), (II), (III) or (IV) | 04-19-2012 |
20120142734 | METHODS FOR TREATING TUMORS WITH THALIDOMIDE - The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally. | 06-07-2012 |
20120142735 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES - The present invention extends to a compound of formula I: | 06-07-2012 |
20120190711 | LENALIDOMIDE SALTS - The present invention relates to acid addition salts of lenalidomide, wherein said acid has a pKa lower than 1, preferably selected from hydrochloric acid, hydrobromic acid, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid and p-toluenesulfonic acid, to processes for their making, and use in medicine, and to purification of lenalidomide base. | 07-26-2012 |
20120232113 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES - The present invention relates to methods of treating or preventing emesis and improving a subject's ASAS score by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. | 09-13-2012 |
20120238603 | TREATMENT FOR INFLAMMATORY BOWEL DISEASE - The present invention relates to a method for the treatment of an inflammatory bowel disease by the administration of the compound [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-yl][7-fluoro-1-(2-methoxyethyl)-4-trifluoromethoxy-1H-indol-3-yl]methanone, which may be represented as Formula I: | 09-20-2012 |
20120252844 | 2,6-DIOXO-3-DEUTERO-PIPERDIN-3-YL-ISOINDOLINE COMPOUNDS - The present application describes 2-(2′,6′-dioxo-3′-deutero-piperidin-3′-yl)isoindoles, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 10-04-2012 |
20120283292 | FATTY ACID LENALIDOMIDE AND THEIR USES - The invention relates to fatty acid lenalidomide derivatives; compositions comprising an effective amount of a fatty acid lenalidomide derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid lenalidomide derivative. | 11-08-2012 |
20120302605 | 3-DEUTERO-POMALIDOMIDE - The present application describes 3′-deutero-pomalidomide, deuterated derivatives thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 11-29-2012 |
20120309790 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS - A treatment for a dermatological allergic condition is disclosed, using a compound of Formula I: | 12-06-2012 |
20130018073 | INDOLE DERIVATIVEAANM Masada; ShinichiAACI KanagawaAACO JPAAGP Masada; Shinichi Kanagawa JPAANM Terao; YoshitoAACI KanagawaAACO JPAAGP Terao; Yoshito Kanagawa JPAANM Murata; ToshikiAACI KanagawaAACO JPAAGP Murata; Toshiki Kanagawa JP - The present invention provides an indole derivative having a melanin-concentrating hormone receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of obesity and the like. | 01-17-2013 |
20130030021 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels - Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal. | 01-31-2013 |
20130059889 | ANHYDROUS LENALIDOMIDE FORM-I - Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1,3-dihydro-isoindole-2-yl)-piperidine-2,6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed. | 03-07-2013 |
20130131112 | SALTS OF 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)PIPERIDINE-2,6-DIONE AND DERIVATIVES THEREOF, OR POLYMORPHS OF SALTS, PROCESS FOR PREPARING SAME AND USE THEREOF - The present invention provides a pharmaceutically acceptable strong acid salt of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione, a solvate thereof, a process for preparing the same and use in the preparation of a medicament for treating diseases or physiological abnormities by inhibiting inflammatory factors or angiogenesis. The water-solubility of the pharmaceutically acceptable strong acid salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione is quite higher than that of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione. The present invention also provides polymorphs of a pharmaceutically acceptable strong acid salt of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and a solvate thereof. | 05-23-2013 |
20130143922 | THIO COMPOUNDS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 06-06-2013 |
20130143923 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION - The present invention related to crystalline forms of thalidomide having a high polymorphic purity and to processes for their preparation. The present invention also relates to pharmaceutical preparations comprising the crystalline forms for the treatment of patients suffering from autoimmune, inflammatory or angiogenic disorders. | 06-06-2013 |
20130150408 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES - This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an immunomodulatory agent. | 06-13-2013 |
20130203811 | THALIDOMIDE AND THALIDOMIDE ANALOGUES FOR THE PREVENTION AND TREATMENT OF SARCOPENIA - The present invention relates to thalidomide and/or thalidomide analogues and methods for using same to maintain or increase muscle mass to prevent and/or treat sarcopenia. The invention also provides pharmaceutical compositions comprising thalidomide and thalidomide analogues for the prevention and/or treatment of sarcopenia. | 08-08-2013 |
20130210862 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS CONTAINING TYROSINE KINASE INHIBITORS AND RELATED METHODS - Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions. | 08-15-2013 |
20130245067 | DEUTERIUM-ENRICHED LENALIDOMIDE - The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 09-19-2013 |
20130253009 | Compositions for Drug Administration - The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. | 09-26-2013 |
20130274289 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA - Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia. | 10-17-2013 |
20130274290 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS - Disclosed herein are compositions and methods for treating a sigma-2 receptor- mediated condition or disorder, including treating one or more symptoms of a sigma-2 receptor-mediated condition or disorder. | 10-17-2013 |
20130274291 | 3'-DEUTERO-POMALIDOMIDE - The present application describes 3′-deutero-pomalidomide, deuterated derivatives thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 10-17-2013 |
20130289068 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS - The present invention relates to method of enhancing the absorption of migraine medications and thereby treating migraines by co-administering to a subject in need thereof an effective amount of a ghrelin mimetic or pharmaceutically acceptable salt, hydrate or solvate thereof and at least one migraine medication selected from a serotonin 5-HT | 10-31-2013 |
20130331415 | COMPOSITIONS COMPRISING WNT INHIBITORS FOR TREATING CANCER - The present invention is directed to compositions for the treatment of cancer, in particular for the treatment of myeloma, lymphoma and leukaemia. The present invention is further directed to the use of said compositions for the manufacture of a medicament for the treatment of cancer and for the use of said compositions in a medicament for treating cancers in animals and humans. | 12-12-2013 |
20140018391 | Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content - The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms. | 01-16-2014 |
20140066480 | METHODS AND MATERIALS FOR ASSESSING RESPONSIVENESS TO LENALIDOMIDE, THALIDOMIDE, AND/OR OTHER THALIDOMIDE ANALOGS - This document provides methods and materials related to assessing responsiveness to lenalidomide, thalidomide, and/or other IMiDs (structural and functional analogues of thalidomide that represent a promising new class of immunomodulators). For example, methods and materials for using CRBN levels to determine whether or not cancer cells (e.g., multiple myeloma cells) are susceptible to lenalidomide, thalidomide, and/or other IMiDs are provided. | 03-06-2014 |
20140113935 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - This invention relates to N-methylaminomethyl-isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed. | 04-24-2014 |
20140121245 | ANHYDROUS LENALIDOMIDE FORM-I - Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1,3-dihydro-isoindole-2-yl)-piperidine-2,6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed. | 05-01-2014 |
20140142141 | DEUTERIUM-ENRICHED LENALIDOMIDE - The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 05-22-2014 |
20140148485 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRANE - Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination. | 05-29-2014 |
20140171466 | PAIN MANAGEMENT IN SICKLE CELL ANEMIA - The present invention relates to a method for the management of pain associated with sickle cell disease. In particular, the method comprises administering to a patient in need of such pain management a therapeutically effective amount of a nociceptin (NOP) receptor agonist or an NOP receptor agonist/mu opioid receptor (MOR) partial agonist. | 06-19-2014 |
20140187584 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels - Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal. | 07-03-2014 |
20140194467 | PLASMA CELL DISORDERS - The invention relates to novel biological markers for plasma cell disorders, such as multiple myeloma, and in particular to the use of microRNAs as diagnostic and prognostic markers in assays for detecting such disorders. The invention also relates to methods of determining the efficacy of treating a plasma cell disorder with a therapeutic agent, and kits for carrying 5 out the assays and methods. The assays are qualitative and/or quantitative, and are adaptable to large-scale screening and clinical trials. | 07-10-2014 |
20140200244 | PHENYLETHANOLAMINE-BASED NMDA RECEPTOR ANTAGONISTS - Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I): | 07-17-2014 |
20140206723 | METHODS FOR TREATING AMYLOIDOSIS WITH 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 07-24-2014 |
20140206724 | METHODS FOR TREATING NON-HODGKIN'S LYMPHOMA WITH 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH A SECOND ACTIVE AGENT - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 07-24-2014 |
20140221427 | ISOTOPOLOGUES OF POMALIDOMIDE - Provided herein are pomalidomide, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided. | 08-07-2014 |
20140275168 | INDIRUBIN DERIVATIVES, AND USES THEREOF - Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities. | 09-18-2014 |
20140296291 | NOVEL CRYSTALLINE FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - The invention relates to novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms. | 10-02-2014 |
20140296292 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR - Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders. | 10-02-2014 |
20140309259 | DERIVATIVES OF 1-(SUBSTITUTED SULFONYL)-2-AMINOIMIDAZOLINE AS ANTITUMOR AND ANTIPROLIFERATIVE AGENTS - The invention provides novel, water-soluble 2-aminoimidazoline derivatives having general Formula (I) as well as some precursors of Formula (I), which are very potent inducers of G2/M cell cycle arrest. In treated tumor cells, compounds of Formula (I) give gene expression profile distinct from known antimitotic agents. The invention also provides methods for preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirably high levels of cell proliferation. The compounds of the invention are also expected to have utility as research tools. | 10-16-2014 |
20140315953 | METHOD AND COMPOSITION FOR TREATING MIGRAINES - A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is designed for inhalation for delivery of drugs to the pulmonary circulation in a rapid and therapeutically effective manner. | 10-23-2014 |
20140336223 | FORMULATIONS OF 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease. | 11-13-2014 |
20150018389 | METHOD FOR TREATING PARKINSONS DISEASE AND OTHER NEUROLOGICAL DISEASES - A method for treating a central nervous system or peripheral nervous system dopaminergic deficit state in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of thalidomide effective in the treatment of a dopaminergic deficit state and for a time sufficient to achieve a suitable blood level to treat said dopaminergic deficit state. | 01-15-2015 |
20150045391 | FILANESIB COMBINED WITH POMALIDOMIDE DISPLAYS ENHANCED ANTI-TUMOR ACTIVITY - A combination of filanesib and pomalidomide for treating patients is provided. | 02-12-2015 |
20150094335 | METHODS FOR TREATING NON-HODGKIN'S LYMPHOMA WITH 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH A SECOND ACTIVE AGENT - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 04-02-2015 |
20150094336 | METHODS FOR TREATING GLIOMAS WITH 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 04-02-2015 |
20150344953 | RNF41 AS A BIOMARKER PREDICTING RESPONSE TO LENALIDOMIDE IN NON-DEL(5Q) MDS - Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS. | 12-03-2015 |
20150359784 | THIO COMPOUNDS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 12-17-2015 |
20160002202 | 2',6'-DIOXO-3'-DEUTERO-PIPERDIN-3-YL-ISOINDOLINE COMPOUNDS - The present application describes 2-(2′,6′-dioxo-3′-deutero-piperidin-3′-yl)isoindoles, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 01-07-2016 |
20160008344 | METHODS FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMAS USING LENALIDOMIDE, AND GENE AND PROTEIN BIOMARKERS AS A PREDICTOR | 01-14-2016 |
20160008345 | METHODS FOR TREATING GLIOMAS WITH 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL))-ISOINDOLINE-1,3-DIONE | 01-14-2016 |
20160015701 | Methods of Treating Acute Kidney Injury - Methods are provided for treating acute kidney injury in a subject, particularly ischemia-induced kidney injury and/or hypoxia-induced kidney injury. The methods comprise administering to the subject an ETA receptor antagonist, such as atrasentan or a pharmaceutically acceptable salt thereof. Methods of diagnosing and treating such kidney injuries are also provided. Methods of reducing or preventing loss of kidney function and/or renal mass or volume, and methods of delaying progression to chronic kidney disease are also provided. | 01-21-2016 |
20160039785 | SOLID FORMS COMPRISING 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed. | 02-11-2016 |
20160067236 | MEDICAL TREATMENTS BASED ON ANAMORELIN - Methods of treating cancer related conditions using anamorelin are described. | 03-10-2016 |
20160096818 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS - Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal. | 04-07-2016 |
20160122318 | ISOINDOLINE INHIBITORS OF ROR-GAMMA - Provided are novel compounds of Formula (I): | 05-05-2016 |
20160152597 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | 06-02-2016 |
20160194301 | PREPARATION OF LENALIDOMIDE | 07-07-2016 |
20160199366 | PRE-FRONTAL CORTEX PROCESSING DISORDER GAIT AND LIMB IMPAIRMENTS TREATMENT | 07-14-2016 |
20220135540 | POLYMORPHS OF AN FXR AGONIST - Provided herein are polymorphs of 6-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid, compositions thereof, methods of preparation thereof, and methods of use thereof. | 05-05-2022 |